http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112763621-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af45ebb3d27a179d347db32926aab90b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c384de2d30578955806c7f3b18da8d4f |
| publicationDate | 2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112763621-A |
| titleOfInvention | Method for determining concentration of dapoxetine in blood plasma by liquid chromatography-mass spectrometry |
| abstract | The invention discloses a method for determining the concentration of dapoxetine in blood plasma by liquid chromatography-mass spectrometry, which comprises the steps of firstly taking a sample to be determined, adding a certain amount of mixed organic solvent for extraction, pretreating, separating by a chromatographic column, and detecting by a mass spectrometer. The method is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of dapoxetine; the plasma standard curve linear range of the method is 2-1000 ng/mL, the precision RSD in batch and between batches is less than +/-15%, and the method is suitable for determining the concentration of dapoxetine in plasma. |
| priorityDate | 2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.